SCHEMBL6599453

SCHEMBL6599453

CN1CCN(C(=O)c2c[nH]cc2-c2cccc3ccccc23)CC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.56
▸ HTR2C P28335 2/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ ALDH1A1 P00352 6/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ GAA P10253 2/20 0.51
▸ GLA P06280 1/20 0.51
▸ CASP1 P29466 1/20 0.51
▸ CASP7 P55210 1/20 0.51
▸ HPGD P15428 2/20 0.48
▸ LMNA P02545 2/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ HRH4 Q9H3N8 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6927839 0.87 MAPK14 (0.47) KDM4EHTR2CL3MBTL1ALDH1A1LMNA
SCHEMBL6922520 0.86 MAPK14 (0.47) KDM4EHTR2CL3MBTL1ALDH1A1LMNA
SCHEMBL6599155 0.86 ALDH1A1 (0.57) KDM4EHTR2CALDH1A1HSD17B10HPGD
SCHEMBL6600644 0.84 LMNA (0.51) KDM4EHTR2CL3MBTL1ALDH1A1HSD17B10
SCHEMBL6599300 0.84 KDM4E (0.47) KDM4EHTR2CL3MBTL1ALDH1A1HSD17B10
SCHEMBL27460024 0.83 KDM4E (0.55) KDM4EHTR2CL3MBTL1ALDH1A1HSD17B10
SCHEMBL3518475 0.82 ALDH1A1 (0.67) KDM4EL3MBTL1ALDH1A1HSD17B10GAA
SCHEMBL6977393 0.76 FNTA (0.57) KDM4EHTR2CL3MBTL1ALDH1A1HSD17B10
SCHEMBL6599085 0.75 MEN1 (0.56) KDM4EL3MBTL1ALDH1A1HSD17B10HPGD
SCHEMBL4453090 0.73 ALDH1A1 (0.77) KDM4EALDH1A1LMNAPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1188407-C Imidazole derivatives with inhabiting activity to transterasa and preparing method thereof LG CHEMICAL LTD (KR) 2005-02-09 — — CN disclosed
EP-1169320-B1 FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF LG CHEM INVESTMENT LTD (KR) 2004-09-22 — — EP disclosed
EP-1045846-B1 IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LTD (KR) 2003-05-02 — — EP disclosed
US-6518429-B2 Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus LG CHEMICAL, LTD. (KR) 2003-02-11 — — US disclosed
US-6511978-B1 For treating cancer, restenosis, atherosclerosis or viral infections LG LIFE SCIENCES, LTD. (KR) 2003-01-28 — — US disclosed
EP-1058683-B1 FARNESYL TRANSFERASE INHIBITORS HAVING A PIPERIDINE STRUCTURE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LTD (KR) 2002-12-04 — — EP disclosed
EP-1169320-A4 FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF LG CHEM INVESTMENT LTD (KR) 2002-10-30 — — EP disclosed
US-6472526-B1 SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES LG CHEMICAL LTD. (KR) 2002-10-29 — — US disclosed
US-20020137769-A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof LG CHEMICAL LTD. 2002-09-26 — — US disclosed
US-6436960-B1 TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS AND INFECTIONS FROM HEPATITIS DELTA AND RELATED VIRUSES. LG CHEMICAL LTD. (KR) 2002-08-20 — — US disclosed
EP-1169320-A1 FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF LG Chem Investment, Ltd. (KR) 2002-01-09 — — EP disclosed
US-6268363-B1 ANTITUMOR LG CHEMICAL LTD. (KR) 2001-07-31 — — US disclosed
CN-1279680-A Imidazole derivatives having farnesyl transferase inhibitory activity and process for producing the same LG CHEMICAL LTD (KR) 2001-01-10 — — CN disclosed
EP-1058683-A1 FARNESYL TRANSFERASE INHIBITORS HAVING A PIPERIDINE STRUCTURE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LIMITED (KR) 2000-12-13 — — EP disclosed
WO-2000064891-A1 FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF LG CHEM INVESTMENT LTD. (KR) 2000-11-02 — — WO disclosed
EP-1045846-A1 IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LIMITED (KR) 2000-10-25 — — EP disclosed
WO-1999038862-A1 FARNESYL TRANSFERASE INHIBITORS HAVING A PIPERIDINE STRUCTURE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LTD. (KR) 1999-08-05 — — WO disclosed
WO-1999028315-A1 IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LTD. (KR) 1999-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137769-A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof FNTA, FNTB, FDPS KDM4E 2589/4885HTR2C 4873/4885L3MBTL1 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback